University Of Notre Dame Du Lac Clovis Oncology, Inc. Transaction History

University Of Notre Dame Du Lac

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $1.3 Million - $2.6 Million	-101,386 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $674,311 - $1.16 Million	-38,183 Reduced 27.36%	101,386 $2.52 Million
Q4 2018 Feb 13, 2019	BUY	$11.63 - $32.67 $687,658 - $1.93 Million	59,128 Added 73.5%	139,569 $2.51 Million
Q3 2018 Nov 13, 2018	BUY	$29.37 - $49.48 $770,786 - $1.3 Million	26,244 Added 48.42%	80,441 $2.36 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $438,938 - $651,206	10,436 Added 23.85%	54,197 $2.46 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $189,052 - $255,439	3,772 Added 9.43%	43,761 $2.31 Million
Q4 2017 Feb 13, 2018	BUY	$57.69 - $84.58 $199,607 - $292,646	3,460 Added 9.47%	39,989 $2.72 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $2.45 Million - $3.1 Million	36,529	36,529 $3.01 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.